

# Pandemic Proposal Weekly Monitor Based on the IMF Staff Discussion Note

7 April 2022\*

\*Based on the IMF SDN "A Proposal to End the COVID-19 Pandemic"


### Overview of the Progress Towards the Targets Identified in the IMF Pandemic Proposal (as of Feb. 2022)

	GOAL	TARGETS	STATUS	IMMEDIATE PRIORITIES
1	Vaccinate	The vaccination targets are to achieve at least 40% coverage in all countries by the end-2021 and 70% by mid-2022	Partial Progress: 40% of countries off track to meet the 70% target by mid-2022	(1) Adequate financing exists for procurement of vaccines (once accounting for large donations, bilateral deals, etc.), but greater financing is needed for delivery, ancillary costs, contingencies, and R&D (2) Incountry delivery challenge is now the key constraint to meet global vaccination targets. Urgent action needed with high-level engagement with country authorities, with flexible financing for in-country vaccine delivery and health systems
2	Test	The diagnostics target is for all countries to achieve testing rates of 1 per 1,000 people per day by the end of 2021 / in 2022; Sequence at least 1% of COVID cases	Insufficient Progress: About 2 out of 3 developing countries off-track on the daily testing target; 67% of countries off-track on the indicative sequencing target	(1) Close financing gaps for existing diagnostics pillar and equitably allocate them to developing countries; (2) Strengthen in-country testing and sequencing capacity
3	Treat	Treat all cases by securing equitable access to treatments on an at-risk basis for 120m patients in developing countries	Insufficient Progress: Granular data not available; but significant gaps in developing countries	(1) Create a pathway for each country to have equitable access to oxygen, the new oral antivirals, and other therapeutics so every country has a complete toolkit to fight COVID-19; (2) Support scale up of local oxygen production and supply; (3) Enhance visibility on in-country demand
4	Prepare	Prepare for emergence of new variants and future threats	Insufficient Progress	(1) Upgrade vaccine portfolio and R&D speed to handle new variants and novel threats; Develop universal vaccine against coronaviruses; (2) Strengthen genomic surveillance especially in developing countries; (3) Diversify regional manufacturing capacity; (4) Create upfront financing mechanism for future pandemics; (4) Continue strengthening in-country health systems based on granular country-level gap assessment

# Financing Gaps & Progress on Dose Sharing

## Funding Needs by Pillar and Major Outcome Category

(in USD billion)



Source and Notes: ACT-A Strategic Plan and Budget. The procurement numbers for the vaccine pillar is based on a common framework to assess and quantify risk factors between COVAX/GMA, the ACT-A Hub, and IMF. Starting in early November 2021, this assessment will be regularly updated and shared to ensure a forward-looking accounting of downside risks and progress towards addressing those risks, and to enhance transparency of the nature and size of the risks. Last Update: 28 Oct 2021

## Dose Donations Pledges and shipped (in millions)

#### **Doses Announced**

#### **Dose Donations Delivered To Date**

#### % Delivered


							Confirmed	Verified By	Pledge at Cardbis	of G7 Summit or	of Total
		Through	Through Direct		Through	<b>Through Direct</b>	Supply by	<b>Country As</b>	Bay G7 Summit or	Jun'21 Pledge	Announced
Country	Total 2021-2022	COVAX	<b>Donations</b>	Total	COVAX	Donations	COVAX**	Of	Jun'21 to COVAX	Delivered	<b>Doses Delivered</b>
Australia	60	41	19	13	-	13	0				22%
Canada	51	51	1	15	14	1	15.1	12/8/21	13	115%	29%
Japan	64	41	23	39	19	21	11.3		30	131%	61%
United Kingdom	107	100	7	36	30	6	26.2	11/8/21	100	36%	34%
United States	900	820	80	321	242	78	693.4		580	55%	36%
European Union	586	496	70	347	297	49	293.6		147	236%	59%
•o/w France	144	138	6	65	62	3	64.1	11/25/21	60	108%	45%
•o/w Germany	175	166	9	103	94	9	99.1		30	342%	59%
•o/w Italy	72	69	3	47	45	3	43.9		15	316%	66%
•o/w Spain	74	64	10	43	40	3	46.3	11/22/21			58%
•o/w Portugal	7	4	3	7	4	3	2.4	11/19/21			92%
•o/w Belgium	15	9	0	9	8	C	8.2				57%
•o/w Finland	4	. 4	-	3	3		- 1.4				69%
•o/w Sweden	11	6	1	8	7	1	5.9	12/2/21			69%
•o/w Denmark	10	5	3	10	7	3	4.7				100%
•o/w Netherlands	32	22	9	21	15	7	16.3	11/24/21			67%
•o/w Ireland	4	. 1	0	2	2	C	1.3				47%
•o/w Others	38	7	26	30	12	19	)				80%
Hong Kong SAR, China	8	8	-	1	1		- 11.5				12%
New Zealand	9	3	1	3	2	C	0.9				29%
Norway	7	5	1	4	3	1					61%
South Korea	5	3	3	2	-	2	<u> </u>				40%
Switzerland	8	4	-	2	2		- 1.6				22%
Turkey	1	9	1	1	-	1	0				100%
UAE	3	1	3	3	-	3	0				91%
India	14		14	14	-	14	. 0				100%
China	130	)	130	100	_	100	0				77%
Other	42	!	19	17	0	17	0				41%
Total	1,996	1,582	371	917	611	306	1054		870	61%	46%

Source: IMF staff calculations based on data from UNICEF, COVAX, country authorities, and various media reports Notes: The US Pfizer doses only includes 40% of the initial 500m contract as donations.

<sup>\*\*</sup> https://www.gavi.org/sites/default/files/covid/covax/COVAX-Dose-Donation-Table.pdf

# Only 37% of COVAX-contracted doses and 21% of AVAT-contracted have been supplied for delivery so far

**COVID-19 Vaccine Supply Tracker: Deliveries to COVAX & AVAT (Mn doses)** 




Sources and Notes: COVAX, UNICEF, Africa CDC, IMF staff calculations. Committed doses are doses that the COVAX facility is required to procure. Support from e US has allowed COVAX to secure 1b Pfizer doses. These include a donation of 700m doses, and the rest 300m doses is treated as non-donations. However, for this presentation all 1b facilitated doses are included in the Pfizer category. The secured supply agreement numbers for SII-AstraZeneca and SII-Novavax are approximated based on COVAX Facility candidate-specific supply information. The dose donations are based on COVAX estimates based on commitments from donors to share doses bilaterally with the COVAX facility.

# Country Level Tracking of Key SDN Targets

## Where are COVID-19 Cases Surging Now?

#### **Ratio of Current Cases to 2020 Peak**




Note: 2020 Peak is Defined as 95% percentile highest daily cases observed in 2020. Country borders or names do not necessarily reflect the IMF's official position. Source: IMF staff calculations, Our World in Data. Last Update: 7 Apr 2022

## **Secured Vaccine Doses and/or Expected Vaccine Supply**

*Target* ≥ 140% of Population

#### Secured Vaccines and/or Expected Vaccine Supply (doses, % of Total Population)




Note: This includes coverage from bilateral contracts, regional deals, COVAX, in-kind donation, domestic production, and contracts supported by MDB financing.

Some contracts are unobserved, which may lead to under-reporting of coverage in some countries. Optional contracts, and unallocated AVAT doses are excluded to remain conservative.

Country borders or names do not necessarily reflect the IMF's official position. Source: IMF-WHO COVID-19 Vaccine Supply Tracker. Last Update: 7 Apr 2022

### **Share Who Received At Least One COVID-19 Vaccine Dose**


#### Share of People Who Received At Least One Vaccine Dose (% of population)



Note: Country borders or names do not necessarily reflect the IMF's official position. Source: Our World in Data. Last Update: 7 Apr 2022

## Vaccine Delivery (1): Daily Speed Observed So Far (Maximum)


#### Maximum Observed Daily Vaccination Rate (per 100 people)



Note: Country borders or names do not necessarily reflect the IMF's official position. Source: IMF staff calculations, Our World in Data. Last Update: 7 Apr 2022

## Vaccine Delivery (2): Daily Speed Observed So Far (Average)


#### **Average Observed Daily Vaccination Rate (per 100 people)**



Note: Country borders or names do not necessarily reflect the IMF's official position. Source: IMF staff calculations, Our World in Data. Last Update: 7 Apr 2022


### Daily Vaccination Rate Needed to Reach 70% by Mid-2022

Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)



Note: J&J and Cansino volumes have been doubled for comparability with the other two dose candidates in the portfolio. Country borders or names do not necessarily reflect the IMF's official position. Source: IMF staff calculations, Our World in Data. Last Update: 7 Apr 2022


## **Current Daily Max vs. Daily Speed Needed**



## **Diagnostics**

## Target = Daily Tests > 1 per 1000 people

#### **Average Daily Tests (per 1000 people)**




Note: Country borders or names do not necessarily reflect the IMF's official position. Source: Our World in Data, FIND. Last Update: 7 Apr 2022

## **Genomic Surveillance: Percent of COVID Cases Sequenced**

Target > 5% of Cases

#### **Genomic Surveillance: Percent of COVID Cases Sequenced**




Note: Country borders or names do not necessarily reflect the IMF's official position. Source: GISAID. Last Update: 7 Apr 2022

## NGS Capacity for SARS-CoV-2 Genomic Surveillance in LMICs


Assessed with a 4-tier country-level classification framework

#### NGS Capacity for SARS-CoV-2 Genomic Surveillance



## Variant VOC Delta: Percent of Delta in past 4 weeks

#### **Variant Genome: Percent of Delta Variant**



Note: Country borders or names do not necessarily reflect the IMF's official position. Source: GISAID. Last Update: 7 Apr 2022

## **Country-Level Dashboard**

Afgnanistan						maicative. Last updated on 7 Ap
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Afghanistan
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	132.8
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	12.8
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	11.38
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	45.27
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	18.52
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	23.35
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.05
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						113
Date approved						Mar 18, 2021
Date effective						Apr 15, 2021
ADB financing for vaccines (USD mn.)						50
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.3
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						.1
Therapeutics – Oxygen (USD mn.)						1.2
Therapeutics – Others (USD mn.)						2.4
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>19</sup>
Date of Publication						Jun, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Albania
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	176.35
Bilateral Deals		2.3	52.9	130.3	475.7	141
Direct Donations		5.2	27.9	35.1	15.3	17.79
COVAX		114.3	87.6	37.1	9.2	17.56
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	42.47
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.33
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	18.37
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.02
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						• 20
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Algeria
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	115.3
Bilateral Deals		2.3	52.9	130.3	475.7	34.85
Direct Donations		5.2	27.9	35.1	15.3	.45
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	13.7
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	40.46
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	26.68
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.06
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.1
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						.1
Therapeutics – Oxygen (USD mn.)						.8
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 2
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Angola
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	192.51
Bilateral Deals		2.3	52.9	130.3	475.7	64.83
Direct Donations		5.2	27.9	35.1	15.3	4.63
COVAX		114.3	87.6	37.1	9.2	104.04
Other		11.3	16.8	23.1	2.1	19
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	17.66
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	46.46
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.11
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	45.24
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.03
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.14
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.21
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						150
Date approved						Jul 29, 2021
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.2
RDT diagnostic tests (USD mn.)						.6
PPE (USD mn.)						5
Therapeutics – Oxygen (USD mn.)						6.1
Therapeutics – Others (USD mn.)						3.2
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 2
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>Antigua and Barbuda</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	250.54
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	149.25
COVAX		114.3	87.6	37.1	9.2	60.77
Other		11.3	16.8	23.1	2.1	40.52
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	62.48
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	51.32
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.34
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.44
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 23
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Argentina
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	325.45
Bilateral Deals		2.3	52.9	130.3	475.7	257.55
Direct Donations		5.2	27.9	35.1	15.3	8.55
COVAX		114.3	87.6	37.1	9.2	15.49
Other		11.3	16.8	23.1	2.1	43.85
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	81.19
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	88.52
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.15
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.42
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	4.3
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.2
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						500
Date approved						Sep 30, 2021
Date effective						Oct 6, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						• 24
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Armenia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	119.49
Bilateral Deals		2.3	52.9	130.3	475.7	60.64
Direct Donations		5.2	27.9	35.1	15.3	43.24
COVAX		114.3	87.6	37.1	9.2	15.61
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	32.31
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	78.82
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.1
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.74
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.8
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.05
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.7
RDT diagnostic tests (USD mn.)						.1
PPE (USD mn.)						.4
Therapeutics – Oxygen (USD mn.)						.5
Therapeutics – Others (USD mn.)						2.6
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						•

- 1 3 3 3				,		<u> </u>
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Aruba
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	•
Bilateral Deals		2.3	52.9	130.3	475.7	•
Direct Donations		5.2	27.9	35.1	15.3	
COVAX		114.3	87.6	37.1	9.2	
Other		11.3	16.8	23.1	2.1	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	76.08
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	9.29
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 26
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Australia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	990.04
Bilateral Deals		2.3	52.9	130.3	475.7	988.05
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	1.99
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	82.73
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	88.43
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.2
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	4.35
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	47.78
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.9
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						•

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Austria
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	72.96
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	51.02
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	39.59
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	5.99
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.34
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 28
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Azerbaijan
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	145.41
Bilateral Deals		2.3	52.9	130.3	475.7	124.16
Direct Donations		5.2	27.9	35.1	15.3	1.47
COVAX		114.3	87.6	37.1	9.2	19.78
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	47.24
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.11
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.41
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.98
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.02
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						2.6
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						.2
Therapeutics – Oxygen (USD mn.)						.1
Therapeutics – Others (USD mn.)						.6
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						

<b>Sahamas, The</b> Notes: The Test Positivity Rate and Genomic Surveillance target						indicative. Last updated on 7 Apr 2
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Bahamas, The
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	163.82
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	113.9
COVAX		114.3	87.6	37.1	9.2	39.84
Other		11.3	16.8	23.1	2.1	10.08
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	39.46
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	61.57
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.37
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	2.22
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 30
Date of Publication						•

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Bahrain
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	215.57
Bilateral Deals		2.3	52.9	130.3	475.7	203.68
Direct Donations		5.2	27.9	35.1	15.3	5.72
COVAX		114.3	87.6	37.1	9.2	6.17
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	69.62
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.48
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	13.36
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.41
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 31
Date of Publication						

Bangladesh		No	tes: The Test Positivi	ty Rate and Genomic S	urveillance targets are i	ndicative. Last updated on 7 Apr 20
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Bangladesh
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	323.31
Bilateral Deals		2.3	52.9	130.3	475.7	143.11
Direct Donations		5.2	27.9	35.1	15.3	18.64
COVAX		114.3	87.6	37.1	9.2	98.59
Other		11.3	16.8	23.1	2.1	62.98
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	68.9
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	47.06
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	1.34
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	27.02
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.04
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	3.37
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.28
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						500
Date approved						Mar 18, 2021
Date effective						Apr 15, 2021
ADB financing for vaccines (USD mn.)						940
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.6
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						10.1
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Low
Risk of Overall Debt Distress						Low 32
Date of Publication						May, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Barbados
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	178.04
Bilateral Deals		2.3	52.9	130.3	475.7	10.43
Direct Donations		5.2	27.9	35.1	15.3	127.7
COVAX		114.3	87.6	37.1	9.2	39.92
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	52.6
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	61.02
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	3.59
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	21.79
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.19
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						•
Date of Publication						

20.0.00				•		·
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Belarus
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	134.93
Bilateral Deals		2.3	52.9	130.3	475.7	103.05
Direct Donations		5.2	27.9	35.1	15.3	31.88
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	57.25
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.27
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	1.03
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	7.92
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.05
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 34
Date of Publication						

2018.0111						· · · · · · · · · · · · · · · · · · ·
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Belgium
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	78.51
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	94.51
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.04
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	3.08
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	30.8
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.64
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 35
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Belize
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	241
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	153.9
COVAX		114.3	87.6	37.1	9.2	50.01
Other		11.3	16.8	23.1	2.1	37.09
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	51.76
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	57.56
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.49
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.84
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.2
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 36
Date of Publication						

Benin		Notes: The Test Positivity Rate and Genomic Surveillance targets are indicative. Last upda						
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Benin		
Vaccines								
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	84.44		
Bilateral Deals		2.3	52.9	130.3	475.7	.83		
Direct Donations		5.2	27.9	35.1	15.3	.8		
COVAX		114.3	87.6	37.1	9.2	80		
Other		11.3	16.8	23.1	2.1	2.81		
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	19.52		
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	84.96		
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.16		
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	19.42		
Progress Towards 70% Full Vaccine Coverage						Off track		
Diagnostics								
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.08		
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•		
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	3.24		
Financing for Vaccines, Diagnostics, Treatments, PPE								
AVAT orders placed						Yes		
World Bank financing for vaccines (USD mn.)						30		
Date approved						Jun 28, 2021		
Date effective						Aug 3, 2021		
ADB financing for vaccines (USD mn.)						•		
Global Fund COVID-19 Response Mechanism								
PCR diagnostic tests (USD mn.)						2.8		
RDT diagnostic tests (USD mn.)						2.3		
PPE (USD mn.)						.6		
Therapeutics – Oxygen (USD mn.)						2.2		
Therapeutics – Others (USD mn.)						0		
IMF-WB Joint Debt Sustainability Analysis								
Risk of External Debt Distress						Moderate		
Risk of Overall Debt Distress						Moderate <sup>37</sup>		
Date of Publication						Dec, 2020		

Driutan			tes. The lest restrict	., riate and cenorine c		idicative. Last updated on 7 Apr
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Bhutan
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	265.18
Bilateral Deals		2.3	52.9	130.3	475.7	52.79
Direct Donations		5.2	27.9	35.1	15.3	132.39
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	74.69
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	87.24
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.14
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	32.44
Progress Towards 70% Full Vaccine Coverage						Goal met
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	12.21
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.3
RDT diagnostic tests (USD mn.)						.2
PPE (USD mn.)						.1
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						39
Date of Publication						Oct, 2018

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Bolivia
	largets	Lic	LIVIIC	Olviic	THE	DOIIVIA
Vaccines  Secured Vaccines (Dasses % of Benyletien)	> 140	122.1	105.3	225.6	F02.2	245.24
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	<b>502.3</b>	98.88
Bilateral Deals		2.3	52.9	130.3	475.7	30.85
Direct Donations		5.2	27.9	35.1	15.3	115.51
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	_
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	49.1
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	57.58
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.11
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	38.26
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics  Deily Testing Pate (non 1000 years)	. 4	06	<u> </u>	4.20	F0.03	20
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.38
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	4.4
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.03
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.9
RDT diagnostic tests (USD mn.)						1.3
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						.8
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 40
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Bosnia and Herzegovina
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	124.23
Bilateral Deals		2.3	52.9	130.3	475.7	27.58
Direct Donations		5.2	27.9	35.1	15.3	86.46
COVAX		114.3	87.6	37.1	9.2	10.19
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	25.93
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	69.21
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.13
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.19
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.38
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 41
Date of Publication						

Botswana		INO	tes. The lest i ositivii	Ly Nate and denomic 3	di veillance targets are n	idicative. Last updated on 7
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Botswana
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	241.5
Bilateral Deals		2.3	52.9	130.3	475.7	37.54
Direct Donations		5.2	27.9	35.1	15.3	95.13
COVAX		114.3	87.6	37.1	9.2	60.75
Other		11.3	16.8	23.1	2.1	48.08
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	53.92
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	88.19
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	3.89
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.9
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	0
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.29
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						

				•	9	·
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Brazil
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	279.29
Bilateral Deals		2.3	52.9	130.3	475.7	208.88
Direct Donations		5.2	27.9	35.1	15.3	2.44
COVAX		114.3	87.6	37.1	9.2	7.12
Other		11.3	16.8	23.1	2.1	60.84
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	75.46
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	80.39
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.33
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.57
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.43
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						• 43
Date of Publication						

				·		
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Brunei Darussalam
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	268.69
Bilateral Deals		2.3	52.9	130.3	475.7	166.14
Direct Donations		5.2	27.9	35.1	15.3	79.72
COVAX		114.3	87.6	37.1	9.2	22.83
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	91.79
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.16
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	6.95
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.29
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 44
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Bulgaria
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	29.75
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	46.56
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.5
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	9.29
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.38
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Burkina Faso
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	123.72
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	3.72
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	5.53
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	53.15
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.38
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	20.08
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	0
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.95
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 4
Date of Publication						Nov, 2020

Burunai		110	tes. The lest Positivi	ty Nate and denomic 3	di velliance targets are ii	Talcative. Last updated of	17 Apr Z
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Burundi	
Vaccines							
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	124.08	
Bilateral Deals		2.3	52.9	130.3	475.7	0	
Direct Donations		5.2	27.9	35.1	15.3	4.08	
COVAX		114.3	87.6	37.1	9.2	120	
Other		11.3	16.8	23.1	2.1	0	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	.08	
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	2.6	
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	0	
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•	
Progress Towards 70% Full Vaccine Coverage						Off track	
Diagnostics							
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.16	
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.69	
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.16	
Financing for Vaccines, Diagnostics, Treatments, PPE							
AVAT orders placed						No	
World Bank financing for vaccines (USD mn.)						•	
Date approved						•	
Date effective						•	
ADB financing for vaccines (USD mn.)						•	
Global Fund COVID-19 Response Mechanism							
PCR diagnostic tests (USD mn.)						4.9	
RDT diagnostic tests (USD mn.)						5.3	
PPE (USD mn.)						7	
Therapeutics – Oxygen (USD mn.)						1.5	
Therapeutics – Others (USD mn.)						.9	
IMF-WB Joint Debt Sustainability Analysis							
Risk of External Debt Distress						High	
Risk of Overall Debt Distress						•••	47
Date of Publication						Mar, 2015	

Cabo Verde		INO	tes: The Test Positivii	y Rate and Genomic 3	urveillance targets are indica	tive. Last updated on 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Cabo Verde
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	191.04
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	99.69
COVAX		114.3	87.6	37.1	9.2	91.35
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	54.6
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	77.02
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.09
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	32.2
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.53
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.73
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)					10	5
Date approved					Jun 29, 2021	Feb 11, 2021
Date effective					Jul 23, 2021	Feb 16, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.1
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						.3
Therapeutics – Others (USD mn.)						.3
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High 48
Date of Publication						Oct, 2020

Cambodia		INO	tes. The fest Positivi	ty Rate and Genomic 3	burveillance targets are i	ndicative. Last updated on 7 Apr 2
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Cambodia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	305.29
Bilateral Deals		2.3	52.9	130.3	475.7	133.42
Direct Donations		5.2	27.9	35.1	15.3	91.87
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	82.86
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.21
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	14.7
Progress Towards 70% Full Vaccine Coverage						Goal met
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.06
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	3.76
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.12
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						3.5
Date approved						Jun 25, 2021
Date effective						Jul 30, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						8.2
RDT diagnostic tests (USD mn.)						.4
PPE (USD mn.)						4.1
Therapeutics – Oxygen (USD mn.)						6.2
Therapeutics – Others (USD mn.)						1.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Low
Risk of Overall Debt Distress						<b>Low</b> 49
Date of Publication						Dec, 2019

COVID-19 Health Tools	<b>Targets</b>	LIC	<b>LMIC</b>	UMIC	HIC	Cameroon
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	120.33
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	.73
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	19.59
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	3.85
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	46.62
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.09
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	3.98
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.04
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.33
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.6
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High 50
Date of Publication						Jul, 2021

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Canada
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	835.96
Bilateral Deals		2.3	52.9	130.3	475.7	827.21
Direct Donations		5.2	27.9	35.1	15.3	2.63
COVAX		114.3	87.6	37.1	9.2	6.13
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	81.97
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	80.61
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.08
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.9
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	19.16
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	7.75
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 51
Date of Publication					_	•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>Cayman Islands</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	•
Bilateral Deals		2.3	52.9	130.3	475.7	•
Direct Donations		5.2	27.9	35.1	15.3	
COVAX		114.3	87.6	37.1	9.2	
Other		11.3	16.8	23.1	2.1	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	87.91
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.07
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.49
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						
Date of Publication						

Chad		No	s: The Test Positivity Rate and Genomic Surveillance targets are indicative. Last updated on 7 Apr				
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Chad	
Vaccines							
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	121.18	
Bilateral Deals		2.3	52.9	130.3	475.7	0	
Direct Donations		5.2	27.9	35.1	15.3	1.18	
COVAX		114.3	87.6	37.1	9.2	120	
Other		11.3	16.8	23.1	2.1	0	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	4.47	
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	100	
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.41	
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	13.38	
Progress Towards 70% Full Vaccine Coverage						Off track	
Diagnostics							
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.02	
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.05	
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.67	
Financing for Vaccines, Diagnostics, Treatments, PPE							
AVAT orders placed						No	
World Bank financing for vaccines (USD mn.)						20	
Date approved						Sep 30, 2021	
Date effective						•	
ADB financing for vaccines (USD mn.)						•	
Global Fund COVID-19 Response Mechanism							
PCR diagnostic tests (USD mn.)						1.4	
RDT diagnostic tests (USD mn.)						.2	
PPE (USD mn.)						.3	
Therapeutics – Oxygen (USD mn.)						3	
Therapeutics – Others (USD mn.)						0	
IMF-WB Joint Debt Sustainability Analysis							
Risk of External Debt Distress						High	
Risk of Overall Debt Distress						High 54	
Date of Publication						Jul, 2020	

Critie		NO	tes. The lest rositivit	.y Nate and Genomic 3	ui veillatice targets are ii	laicative. Last apaated on
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Chile
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	437.78
Bilateral Deals		2.3	52.9	130.3	475.7	425.77
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	12.01
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	90.59
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	100
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.23
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	3.04
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	8.01
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.66
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						

				*		
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	China
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	250.31
Bilateral Deals		2.3	52.9	130.3	475.7	57.23
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	193.08
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	86.08
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.23
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.5
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.2
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 56
Date of Publication						•

				*		
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Colombia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	174.35
Bilateral Deals		2.3	52.9	130.3	475.7	96.89
Direct Donations		5.2	27.9	35.1	15.3	24.38
COVAX		114.3	87.6	37.1	9.2	53.08
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	68.19
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.17
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.35
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	2
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.25
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						1
Therapeutics – Oxygen (USD mn.)						.9
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 5
Date of Publication						•

Comoros		110	tes. The lest i ositivi	Ty Nate and Genomic 5		ndicative. Last apaated on 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Comoros
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	133.77
Bilateral Deals		2.3	52.9	130.3	475.7	22.51
Direct Donations		5.2	27.9	35.1	15.3	11.26
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	33.9
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	62.3
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	0
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	0
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.01
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.42
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						21
Date approved						Jun 29, 2021
Date effective						Jul 15, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 58
Date of Publication						Apr, 2020

Congo, Rep		INO	tes. The lest Positiving	ty Nate and Genomic 3	bul veillance targets are	Indicative. Last updated on 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Congo, Rep
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	151.54
Bilateral Deals		2.3	52.9	130.3	475.7	21.94
Direct Donations		5.2	27.9	35.1	15.3	7.07
COVAX		114.3	87.6	37.1	9.2	106.03
Other		11.3	16.8	23.1	2.1	16.51
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	12.04
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	54.37
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	1.04
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	27.74
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.27
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						12
Date approved						Jun 2, 2021
Date effective						Aug 27, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						2.1
RDT diagnostic tests (USD mn.)						.1
PPE (USD mn.)						2.2
Therapeutics – Oxygen (USD mn.)						1
Therapeutics – Others (USD mn.)						.8
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						In distress
Risk of Overall Debt Distress						In distress 60
Date of Publication						Jan, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Costa Rica
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	295.76
Bilateral Deals		2.3	52.9	130.3	475.7	204.32
Direct Donations		5.2	27.9	35.1	15.3	41.62
COVAX		114.3	87.6	37.1	9.2	49.81
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	78
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	78.99
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.44
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.32
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	7.6
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.43
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						.5
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						•
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	<b>LMIC</b>	UMIC	HIC	Cote d'Ivoire
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	120.21
Bilateral Deals		2.3	52.9	130.3	475.7	4.07
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	36.15
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	17
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	50.12
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	32.12
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.05
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.53
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.89
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						100
Date approved						Apr 16, 2021
Date effective						May 27, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 62
Date of Publication						Jul, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Croatia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	54.86
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	63.6
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	26.23
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.68
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 63
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	<b>LMIC</b>	UMIC	HIC	Cuba
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	344.63
Bilateral Deals		2.3	52.9	130.3	475.7	204.63
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	140
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	87.63
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.13
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.11
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.11
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						•
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Cyprus
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	645.06
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	16.12
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	72.02
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	62.01
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.15
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	68.13
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	5.07
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.16
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 65
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Czech Republic
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	630.3
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	1.36
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	63.98
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	66.49
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.21
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	23.5
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.94
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						•
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Denmark
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	82.58
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	100
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.92
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	15.19
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	14.95
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						•
Date of Publication						

COVID 10 Health Tools	Torgoto			•		D''L - L'
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Djibouti
Vaccines						100.00
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	109.93
Bilateral Deals		2.3	52.9	130.3	475.7	9.98
Direct Donations		5.2	27.9	35.1	15.3	19.96
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	10.95
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	29.81
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	31.48
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.33
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.22
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	4.41
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.7
RDT diagnostic tests (USD mn.)						.2
PPE (USD mn.)						.2
Therapeutics – Oxygen (USD mn.)						.4
Therapeutics – Others (USD mn.)						.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High
Date of Publication						May, 2020

Dominica		NO	tes: The Test Positivii	Ly Rate and Genomic S	urveillance targets are ir	ndicative. Last updated on	/ Apr 2
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Dominica	
Vaccines							
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	356.4	
Bilateral Deals		2.3	52.9	130.3	475.7	0	
Direct Donations		5.2	27.9	35.1	15.3	215.18	
COVAX		114.3	87.6	37.1	9.2	141.22	
Other		11.3	16.8	23.1	2.1	0	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	41.58	
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	29.78	
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.53	
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	70.6	
Progress Towards 70% Full Vaccine Coverage						Off track	
Diagnostics							
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	3.37	
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•	
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.25	
Financing for Vaccines, Diagnostics, Treatments, PPE							
AVAT orders placed						•	
World Bank financing for vaccines (USD mn.)						•	
Date approved						•	
Date effective							
ADB financing for vaccines (USD mn.)						•	
Global Fund COVID-19 Response Mechanism							
PCR diagnostic tests (USD mn.)							
RDT diagnostic tests (USD mn.)							
PPE (USD mn.)							
Therapeutics – Oxygen (USD mn.)							
Therapeutics – Others (USD mn.)						•	
IMF-WB Joint Debt Sustainability Analysis							
Risk of External Debt Distress						High	
Risk of Overall Debt Distress						•••	69
Date of Publication						Jun, 2018	

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Ecuador
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	273.31
Bilateral Deals		2.3	52.9	130.3	475.7	132.22
Direct Donations		5.2	27.9	35.1	15.3	23
COVAX		114.3	87.6	37.1	9.2	34.01
Other		11.3	16.8	23.1	2.1	84.09
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	77.19
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	68.92
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.42
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.6
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	17.2
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.59
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						150
Date approved						Apr 1, 2021
Date effective						May 20, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						.6
PPE (USD mn.)						.6
Therapeutics – Oxygen (USD mn.)						.5
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 71
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Egypt, Arab Rep
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	230.91
Bilateral Deals		2.3	52.9	130.3	475.7	91.12
Direct Donations		5.2	27.9	35.1	15.3	7.96
COVAX		114.3	87.6	37.1	9.2	87.07
Other		11.3	16.8	23.1	2.1	44.76
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	30.89
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	88.86
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.21
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	41.64
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.15
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	7.4
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	36
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.9
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 7
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	El Salvador
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	253.21
Bilateral Deals		2.3	52.9	130.3	475.7	144.82
Direct Donations		5.2	27.9	35.1	15.3	28.39
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	65.79
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	80.92
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.2
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	27.66
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.76
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.9
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.28
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						50
Date approved						Apr 16, 2021
Date effective						Sep 23, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						1.5
Therapeutics – Oxygen (USD mn.)						.1
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 73
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>Equatorial Guinea</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	56.56
Bilateral Deals		2.3	52.9	130.3	475.7	35.87
Direct Donations		5.2	27.9	35.1	15.3	20.69
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	14.53
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	57.73
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.3
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.06
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.33
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						• 74
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Eritrea
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	120
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	•
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	•
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	0
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						•
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.03
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 75
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Estonia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	63.65
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	70.9
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.43
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	29.6
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.88
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 70
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Eswatini
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	124.35
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	44.35
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	27.16
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	67.42
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	32.74
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.6
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	3.94
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.78
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						8
Date approved						Apr 16, 2021
Date effective						Oct 11, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.8
RDT diagnostic tests (USD mn.)						.2
PPE (USD mn.)						1.9
Therapeutics – Oxygen (USD mn.)						1.8
Therapeutics – Others (USD mn.)						.3
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						• 77
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Ethiopia	
Vaccines							
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	105.85	
Bilateral Deals		2.3	52.9	130.3	475.7	0	
Direct Donations		5.2	27.9	35.1	15.3	3.31	
COVAX		114.3	87.6	37.1	9.2	100	
Other		11.3	16.8	23.1	2.1	2.55	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	17.78	
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	68.39	
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03	
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	20.3	
Progress Towards 70% Full Vaccine Coverage						Off track	
Diagnostics							
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.04	
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.48	
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.13	
Financing for Vaccines, Diagnostics, Treatments, PPE							
AVAT orders placed						Yes	
World Bank financing for vaccines (USD mn.)						•	
Date approved							
Date effective						•	
ADB financing for vaccines (USD mn.)						•	
Global Fund COVID-19 Response Mechanism							
PCR diagnostic tests (USD mn.)						10	
RDT diagnostic tests (USD mn.)						20.3	
PPE (USD mn.)						30.4	
Therapeutics – Oxygen (USD mn.)						26.5	
Therapeutics – Others (USD mn.)						5.9	
IMF-WB Joint Debt Sustainability Analysis							
Risk of External Debt Distress						High	
Risk of Overall Debt Distress						High	78
Date of Publication						Apr, 2020	

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>Faroe Islands</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	•
Bilateral Deals		2.3	52.9	130.3	475.7	
Direct Donations		5.2	27.9	35.1	15.3	
COVAX		114.3	87.6	37.1	9.2	
Other		11.3	16.8	23.1	2.1	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	83.37
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	•
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						•
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	14.66
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.12
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Fiji
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	268.28
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	188.28
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	69.59
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	81.58
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	1.1
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	27.74
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.1
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.82
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 80
Date of Publication						

						· · ·
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Finland
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	77.73
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	87.62
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.2
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	56.1
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	3.2
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 81
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	France
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	77.82
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	71.97
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	7.98
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	30.9
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.01
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 8.
Date of Publication						

				<u>*                                    </u>		<u> </u>
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Gabon
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	113.75
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	27.21
COVAX		114.3	87.6	37.1	9.2	45.07
Other		11.3	16.8	23.1	2.1	41.48
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	11.05
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	39.9
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.36
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.06
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.18
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.3
RDT diagnostic tests (USD mn.)						.1
PPE (USD mn.)						.1
Therapeutics – Oxygen (USD mn.)						.1
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 8.
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Gambia, The
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	130.72
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	10.72
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	12.79
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	82.36
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	0
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	18.4
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.03
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.05
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	10.25
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						8
Date approved						Apr 16, 2021
Date effective						May 6, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						2.1
RDT diagnostic tests (USD mn.)						2.6
PPE (USD mn.)						3
Therapeutics – Oxygen (USD mn.)						.8
Therapeutics – Others (USD mn.)						.5
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>84</sup>
Date of Publication						Jan, 2022

000.8.0				,		'
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Georgia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	142.12
Bilateral Deals		2.3	52.9	130.3	475.7	103.02
Direct Donations		5.2	27.9	35.1	15.3	35.08
COVAX		114.3	87.6	37.1	9.2	4.02
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	31.6
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	79.71
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	3.09
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	11.87
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.11
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						15
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.8
RDT diagnostic tests (USD mn.)						2.2
PPE (USD mn.)						.6
Therapeutics – Oxygen (USD mn.)						.4
Therapeutics – Others (USD mn.)						.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 8
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Germany
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	664.69
Bilateral Deals		2.3	52.9	130.3	475.7	664.69
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	75.34
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	79.49
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	3.94
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	55.4
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.38
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						•
Date of Publication						•

Ghana		INO	tes. The lest Positivit	.y Nate and Genomic 3	di veillance targets are	ndicative. Last updated on 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Ghana
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	142.67
Bilateral Deals		2.3	52.9	130.3	475.7	.95
Direct Donations		5.2	27.9	35.1	15.3	8.4
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	53.32
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	15.98
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	51.9
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.12
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	32.16
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.49
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.11
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						200
Date approved						Jun 10, 2021
Date effective						Jul 15, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.3
RDT diagnostic tests (USD mn.)						.2
PPE (USD mn.)						2.3
Therapeutics – Oxygen (USD mn.)						10.9
Therapeutics – Others (USD mn.)						1.3
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High 87
Date of Publication						Jul, 2021

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Gibraltar
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	•
Bilateral Deals		2.3	52.9	130.3	475.7	
Direct Donations		5.2	27.9	35.1	15.3	•
COVAX		114.3	87.6	37.1	9.2	•
Other		11.3	16.8	23.1	2.1	•
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	122.61
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.74
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						•
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	15.91
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	8.58
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	15.98
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 88
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Greece
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	73.31
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	74.47
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.13
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Goal met
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	25.16
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	7.7
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.53
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 89
Date of Publication						

0.0.000				,		<u> </u>
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Grenada
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	171.25
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	51.98
COVAX		114.3	87.6	37.1	9.2	119.27
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	33.6
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	46.67
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	55.18
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	7.11
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.41
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						In distress
Risk of Overall Debt Distress						In distress 90
Date of Publication						Apr, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Guatemala
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	133.68
Bilateral Deals		2.3	52.9	130.3	475.7	43.84
Direct Donations		5.2	27.9	35.1	15.3	50.19
COVAX		114.3	87.6	37.1	9.2	39.66
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	32.88
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	84.72
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.37
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.53
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	19.11
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.22
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 9
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	<b>LMIC</b>	UMIC	HIC	Guinea
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	149.53
Bilateral Deals		2.3	52.9	130.3	475.7	17.04
Direct Donations		5.2	27.9	35.1	15.3	3.1
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	29.39
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	18.37
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	77.19
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.14
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	33.5
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.03
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.53
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.45
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						28.2
Date approved						Jun 29, 2021
Date effective						Aug 17, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 92
Date of Publication						Jun, 2021

Guinea-Bissau		110	tes. The restriction	ty hate and denotine s	an vemanee targets are	indicative. Last updated on 7 A
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Guinea-Bissau
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	161.53
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	25.4
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	16.13
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	16.94
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	56
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	0
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	26.44
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.1
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	2.61
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.59
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						5
Date approved						Jun 29, 2021
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.7
RDT diagnostic tests (USD mn.)						.1
PPE (USD mn.)						3.2
Therapeutics – Oxygen (USD mn.)						.9
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High 93
Date of Publication						Jan, 2023

Guyana		INO	tes. The Test Positivi	ty Rate and Genomic 3	burveillance targets are	ndicative. Last updated on 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Guyana
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	240.26
Bilateral Deals		2.3	52.9	130.3	475.7	113.88
Direct Donations		5.2	27.9	35.1	15.3	42.27
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	4.11
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	45.76
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	83.59
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	23.3
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.07
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.23
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						5
Date approved						Jun 29, 2021
Date effective						Sep 30, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.4
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						1.1
Therapeutics – Others (USD mn.)						.2
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 94
Date of Publication						Aug, 2019

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Haiti
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	100
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	.99
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	31.93
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	5.84
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.03
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.34
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.61
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High 9
Date of Publication						Apr, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Honduras
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	212.05
Bilateral Deals		2.3	52.9	130.3	475.7	126.2
Direct Donations		5.2	27.9	35.1	15.3	5.84
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	45.54
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	25.86
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.11
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.05
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						20
Date approved						Apr 16, 2021
Date effective						Sep 30, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Low
Risk of Overall Debt Distress						<b>Low</b> 96
Date of Publication						Sep, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Hong Kong SAR, China
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	275.39
Bilateral Deals		2.3	52.9	130.3	475.7	275.39
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	77.59
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	82.47
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.66
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						•
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	23.54
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	24
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 97
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Hungary
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	701.59
Bilateral Deals		2.3	52.9	130.3	475.7	701.59
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	64.24
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	50.35
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.92
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	19.98
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.03
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 98
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Iceland
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	307.11
Bilateral Deals		2.3	52.9	130.3	475.7	307.11
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	78.69
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	81.29
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	3.62
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	5.37
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 99
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	<b>LMIC</b>	UMIC	HIC	India	
Vaccines							
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	200.78	
Bilateral Deals		2.3	52.9	130.3	475.7	179.13	
Direct Donations		5.2	27.9	35.1	15.3	.12	
COVAX		114.3	87.6	37.1	9.2	21.53	
Other		11.3	16.8	23.1	2.1	0	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	59.97	
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.9	
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.15	
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•	
Progress Towards 70% Full Vaccine Coverage						On track	
Diagnostics							
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.34	
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.22	
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.39	
Financing for Vaccines, Diagnostics, Treatments, PPE							
AVAT orders placed						•	
World Bank financing for vaccines (USD mn.)						•	
Date approved						•	
Date effective							
ADB financing for vaccines (USD mn.)						•	
Global Fund COVID-19 Response Mechanism							
PCR diagnostic tests (USD mn.)						0	
RDT diagnostic tests (USD mn.)						0	
PPE (USD mn.)						0	
Therapeutics – Oxygen (USD mn.)						75	
Therapeutics – Others (USD mn.)						0	
IMF-WB Joint Debt Sustainability Analysis							
Risk of External Debt Distress							
Risk of Overall Debt Distress							100
Date of Publication							

				,		<u>'</u>
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Indonesia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	216.6
Bilateral Deals		2.3	52.9	130.3	475.7	128.71
Direct Donations		5.2	27.9	35.1	15.3	7.89
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	58.16
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.35
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	30.12
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.44
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	8.37
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.38
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						509.9
Date approved						Jun 17, 2021
Date effective						Aug 19, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						3
Therapeutics – Oxygen (USD mn.)						6.8
Therapeutics – Others (USD mn.)						2.7
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 101
Date of Publication						

Iran, Islamic Rep		No	tes: The Test Positivi	ty Rate and Genomic S	urveillance targets are	e indicative. Last updated on 7 Apr 20
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Iran, Islamic Rep
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	220.88
Bilateral Deals		2.3	52.9	130.3	475.7	188.04
Direct Donations		5.2	27.9	35.1	15.3	10.65
COVAX		114.3	87.6	37.1	9.2	22.19
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	67.07
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.12
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.7
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	4.01
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.02
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.2
RDT diagnostic tests (USD mn.)						.2
PPE (USD mn.)						.1
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						.2
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 102
Date of Publication						

				,	9	' '
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Iraq
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	94.68
Bilateral Deals		2.3	52.9	130.3	475.7	41.28
Direct Donations		5.2	27.9	35.1	15.3	1.82
COVAX		114.3	87.6	37.1	9.2	25.59
Other		11.3	16.8	23.1	2.1	25.98
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	17.59
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.9
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.21
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	5.02
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.02
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						100
Date approved						Sep 24, 2021
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 103
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Ireland
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	80.54
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	87.23
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.1
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.32
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	38.81
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	4.29
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 104
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Isle of Man
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	•
Bilateral Deals		2.3	52.9	130.3	475.7	
Direct Donations		5.2	27.9	35.1	15.3	
COVAX		114.3	87.6	37.1	9.2	•
Other		11.3	16.8	23.1	2.1	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	78.47
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	•
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						•
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Israel
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	554.05
Bilateral Deals		2.3	52.9	130.3	475.7	554.05
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	65.99
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	41.82
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	18.2
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.47
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 10
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Italy
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	744.89
Bilateral Deals		2.3	52.9	130.3	475.7	744.89
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	79.26
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	95.79
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	10.46
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	14.85
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.73
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 107
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Jamaica
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	182.24
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	53.6
COVAX		114.3	87.6	37.1	9.2	62.31
Other		11.3	16.8	23.1	2.1	66.33
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	22.76
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	38.14
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.39
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.9
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.81
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 108
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Japan
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	699.72
Bilateral Deals		2.3	52.9	130.3	475.7	699.72
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	79.98
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	97.99
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.55
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	36.83
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	3.7
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 109
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	<b>LMIC</b>	UMIC	HIC	Jordan
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	128.33
Bilateral Deals		2.3	52.9	130.3	475.7	111.99
Direct Donations		5.2	27.9	35.1	15.3	11.69
COVAX		114.3	87.6	37.1	9.2	4.65
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	43.4
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	4.23
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	13.01
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.08
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						63.75
Date approved						Jun 16, 2021
Date effective						Oct 5, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 110
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Kazakhstan
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	140
Bilateral Deals		2.3	52.9	130.3	475.7	74.91
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	65.09
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	48.35
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.15
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	4
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.04
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.3
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						2
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						.6
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 111
Date of Publication						

Kenya					a. veaee ta. gets a. e .	Tidicative. Last updated off 7 Apr 2
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Kenya
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	117.39
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	13.14
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	24.25
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	14.86
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	70.76
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	28.8
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.07
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.3
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.59
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						130
Date approved						Jun 28, 2021
Date effective						Oct 13, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						13
RDT diagnostic tests (USD mn.)						8.9
PPE (USD mn.)						6.7
Therapeutics – Oxygen (USD mn.)						41.5
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>112</sup>
Date of Publication						Apr, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Kiribati
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	214.86
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	84.85
COVAX		114.3	87.6	37.1	9.2	130.01
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	45.58
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	66.06
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.16
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	54.7
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>113</sup>
Date of Publication						Jan, 2019

COVID 10 Health Tools	Towasta	ШС	INAIC	LINAIC	1110	
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Korea, Rep
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	441.24
Bilateral Deals		2.3	52.9	130.3	475.7	432.7
Direct Donations		5.2	27.9	35.1	15.3	3.63
COVAX		114.3	87.6	37.1	9.2	4.91
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	86.75
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	89.1
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Goal met
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.86
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	66.5
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.28
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 114
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Kuwait
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	200.24
Bilateral Deals		2.3	52.9	130.3	475.7	199.43
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	.81
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	75.94
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.14
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.12
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	5.97
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.08
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 115
Date of Publication						

Direct Boriations		3.2	27.5	33.1	13.3		
COVAX		114.3	87.6	37.1	9.2	80	
Other		11.3	16.8	23.1	2.1	3.02	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	18.83	
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	48.75	
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.07	
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	16.34	
Progress Towards 70% Full Vaccine Coverage						Off track	
Diagnostics							
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	3.39	
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•	
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.06	
Financing for Vaccines, Diagnostics, Treatments, PPE							
AVAT orders placed						•	
World Bank financing for vaccines (USD mn.)						20	
Date approved						Jun 3, 2021	
Date effective						Sep 22, 2021	
ADB financing for vaccines (USD mn.)						•	
Global Fund COVID-19 Response Mechanism							
PCR diagnostic tests (USD mn.)						.6	
RDT diagnostic tests (USD mn.)						.1	
PPE (USD mn.)						.4	
Therapeutics – Oxygen (USD mn.)						0	
Therapeutics – Others (USD mn.)						2.6	
IMF-WB Joint Debt Sustainability Analysis							
Risk of External Debt Distress						Moderate	
Risk of Overall Debt Distress						Moderate 116	
Date of Publication						Jun, 2021	

Lao PDR		INO	tes. The lest Positivii	ty Kate and Genomic 3	bui veillance targets are i	ndicative. Last updated on 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Lao PDR
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	225.21
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	125.21
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	62.06
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	64.44
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.24
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	56.44
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.12
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	87.67
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.01
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						15
Date approved						Jun 9, 2021
Date effective						Jul 22, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.7
RDT diagnostic tests (USD mn.)						.8
PPE (USD mn.)						1.3
Therapeutics – Oxygen (USD mn.)						.8
Therapeutics – Others (USD mn.)						.3
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>117</sup>
Date of Publication						Aug, 2019

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Latvia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	639.72
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	10.78
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	69.78
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	59.03
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.59
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	27.79
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.62
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 118
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Lebanon
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	85.98
Bilateral Deals		2.3	52.9	130.3	475.7	16.33
Direct Donations		5.2	27.9	35.1	15.3	12.37
COVAX		114.3	87.6	37.1	9.2	24.03
Other		11.3	16.8	23.1	2.1	33.25
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	32.62
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.9
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.17
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.13
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						34
Date approved						Jan 20, 2021
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 119
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Lesotho
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	172.9
Bilateral Deals		2.3	52.9	130.3	475.7	9.26
Direct Donations		5.2	27.9	35.1	15.3	12.2
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	71.44
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	33.7
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	55.99
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	32.72
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.26
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.39
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.07
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						25.5
Date approved						Jun 1, 2021
Date effective						Jun 30, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 120
Date of Publication						Jul, 2020

Liberia		110				ndicative. Last updated on 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Liberia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	127.98
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	.52
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	7.46
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	20.94
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	100
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	1.5
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	22.48
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.03
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.5
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						8
Date approved						Jun 30, 2021
Date effective						Aug 3, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.9
RDT diagnostic tests (USD mn.)						.2
PPE (USD mn.)						3.4
Therapeutics – Oxygen (USD mn.)						4
Therapeutics – Others (USD mn.)						2
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						High <sup>121</sup>
Date of Publication						Dec, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Libya
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	135.17
Bilateral Deals		2.3	52.9	130.3	475.7	69.84
Direct Donations		5.2	27.9	35.1	15.3	10.51
COVAX		114.3	87.6	37.1	9.2	54.82
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	16.32
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	59.72
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.01
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 122
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Lithuania
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	69.64
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	48.8
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.9
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	33
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	3.55
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						•
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Luxembourg
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	72.57
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	73.68
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.04
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Goal met
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	398.67
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	36.4
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	11.49
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						
Date of Publication						

				•		· · · · · · · · · · · · · · · · · · ·
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Macao SAR, China
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	•
Bilateral Deals		2.3	52.9	130.3	475.7	•
Direct Donations		5.2	27.9	35.1	15.3	
COVAX		114.3	87.6	37.1	9.2	
Other		11.3	16.8	23.1	2.1	•
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	79.1
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	•
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.54
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						•
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 125
Date of Publication						•

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Madagascar
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	101.06
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	1.06
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	3.7
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	55.27
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.29
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	11
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	2.64
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.24
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						100
Date approved						Jun 24, 2021
Date effective						Jul 26, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						2.8
RDT diagnostic tests (USD mn.)						.5
PPE (USD mn.)						1.8
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						1.7
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 126
Date of Publication						Mar, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Malawi
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	100.77
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	.77
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	4.39
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	49.56
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	17.38
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.75
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.36
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						30
Date approved						Jun 15, 2021
Date effective						Aug 23, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						10.1
RDT diagnostic tests (USD mn.)						6.8
PPE (USD mn.)						5.7
Therapeutics – Oxygen (USD mn.)						1.6
Therapeutics – Others (USD mn.)						1.2
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						High <sup>127</sup>
Date of Publication						Oct, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Malaysia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	289.1
Bilateral Deals		2.3	52.9	130.3	475.7	262.69
Direct Donations		5.2	27.9	35.1	15.3	20.79
COVAX		114.3	87.6	37.1	9.2	5.62
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	78.88
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	82.73
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.12
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.56
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	13.52
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.29
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 12
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Maldives
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	438.59
Bilateral Deals		2.3	52.9	130.3	475.7	183.95
Direct Donations		5.2	27.9	35.1	15.3	73.58
COVAX		114.3	87.6	37.1	9.2	181.05
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	70.56
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	77.18
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.31
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	53.5
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	7.96
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	12.16
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.7
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>129</sup>
Date of Publication						Apr, 2020

IVIAII		110	tes. The lest i ositivit	.y Nate and denomic 5	ar vemarice targets are	indicative. Last updated on 7 Apr 2
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Mali
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	123.36
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	3.36
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	4.69
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	51.94
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.04
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	10.26
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.04
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.31
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.24
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						30
Date approved						Sep 23, 2021
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.6
RDT diagnostic tests (USD mn.)						.1
PPE (USD mn.)						1.6
Therapeutics – Oxygen (USD mn.)						1
Therapeutics – Others (USD mn.)						.4
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate <sup>130</sup>
Date of Publication						Feb, 2021

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Malta
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	90.47
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	94.9
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	6.49
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	20.85
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.07
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 131
Date of Publication						•

Marshall Islands		110	tes. The restriction			e marcative. Last updated on 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Marshall Islands
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	107.6
Bilateral Deals		2.3	52.9	130.3	475.7	7.6
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	39
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	77.5
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	•
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.12
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>132</sup>
Date of Publication						May, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Mauritania
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	101.91
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	7.02
COVAX		114.3	87.6	37.1	9.2	87.49
Other		11.3	16.8	23.1	2.1	7.41
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	22.25
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	70.02
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	38.6
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.01
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.52
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.05
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						15
Date approved						Jun 30, 2021
Date effective						Aug 6, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>133</sup>
Date of Publication						Sep, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Mauritius
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	425.38
Bilateral Deals		2.3	52.9	130.3	475.7	274.85
Direct Donations		5.2	27.9	35.1	15.3	16.1
COVAX		114.3	87.6	37.1	9.2	45.3
Other		11.3	16.8	23.1	2.1	89.13
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	76.18
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	73.55
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.29
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	0
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.61
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						•
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Mexico
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	239.17
Bilateral Deals		2.3	52.9	130.3	475.7	210.19
Direct Donations		5.2	27.9	35.1	15.3	10.12
COVAX		114.3	87.6	37.1	9.2	18.86
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	61.19
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	78.68
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.21
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.08
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	12.3
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.03
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						· 135
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Micronesia, Fed Sts
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	103.08
Bilateral Deals		2.3	52.9	130.3	475.7	3.08
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	38.81
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	100
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	•
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>136</sup>

Aug, 2019

Date of Publication

iviolativa				•		indicative. Last apaated on 7 Apr 2
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Moldova
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	135.78
Bilateral Deals		2.3	52.9	130.3	475.7	24.87
Direct Donations		5.2	27.9	35.1	15.3	27.18
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	3.73
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	26.25
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	88.53
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	29
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.22
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.1
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						30
Date approved						Apr 23, 2021
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.3
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						.5
Therapeutics – Oxygen (USD mn.)						.6
Therapeutics – Others (USD mn.)						.6
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Low
Risk of Overall Debt Distress						Low 137
Date of Publication						Apr, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Mongolia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	253.61
Bilateral Deals		2.3	52.9	130.3	475.7	91.01
Direct Donations		5.2	27.9	35.1	15.3	22.53
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	60.07
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	65.32
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.68
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	19.94
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.22
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	6.71
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.1
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						50.7
Date approved						Feb 11, 2021
Date effective						Jun 8, 2021
ADB financing for vaccines (USD mn.)						19
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.7
RDT diagnostic tests (USD mn.)						.5
PPE (USD mn.)						.3
Therapeutics – Oxygen (USD mn.)						.5
Therapeutics – Others (USD mn.)						.5
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 138
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Montenegro
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	176.67
Bilateral Deals		2.3	52.9	130.3	475.7	71.84
Direct Donations		5.2	27.9	35.1	15.3	89.16
COVAX		114.3	87.6	37.1	9.2	15.67
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	44.89
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	63.2
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.7
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.27
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						•
Date of Publication						•

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Morocco
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	261.75
Bilateral Deals		2.3	52.9	130.3	475.7	181.75
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	62.56
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	96.42
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	25.2
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.21
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.12
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.06
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						1.3
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 140
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Mozambique
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	215.41
Bilateral Deals		2.3	52.9	130.3	475.7	34.2
Direct Donations		5.2	27.9	35.1	15.3	7.33
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	53.88
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	41.11
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	94.02
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.36
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	42.32
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.63
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.51
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						115
Date approved						Jun 3, 2021
Date effective						Jun 29, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						28.7
RDT diagnostic tests (USD mn.)						4.2
PPE (USD mn.)						5.3
Therapeutics – Oxygen (USD mn.)						7.6
Therapeutics – Others (USD mn.)						8.9
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						In distress
Risk of Overall Debt Distress						In distress 141
Date of Publication						Apr, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Myanmar
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	256.73
Bilateral Deals		2.3	52.9	130.3	475.7	128.09
Direct Donations		5.2	27.9	35.1	15.3	28.65
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	40.18
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.22
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	26.76
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.23
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.31
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.01
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						3
RDT diagnostic tests (USD mn.)						6.9
PPE (USD mn.)						27.6
Therapeutics – Oxygen (USD mn.)						5.9
Therapeutics – Others (USD mn.)						2
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Low
Risk of Overall Debt Distress						Low 142
Date of Publication						Jan, 2024

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Namibia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	76.48
Bilateral Deals		2.3	52.9	130.3	475.7	9.66
Direct Donations		5.2	27.9	35.1	15.3	26.59
COVAX		114.3	87.6	37.1	9.2	27.35
Other		11.3	16.8	23.1	2.1	12.88
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	14.94
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	61.21
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.04
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.32
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.12
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.19
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.2
RDT diagnostic tests (USD mn.)						.2
PPE (USD mn.)						1
Therapeutics – Oxygen (USD mn.)						2.7
Therapeutics – Others (USD mn.)						.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 1
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Netherlands
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	72.11
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	<b>72.66</b>
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.04
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	12.41
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	61.7
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.41
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						•
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>New Caledonia</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	•
Bilateral Deals		2.3	52.9	130.3	475.7	•
Direct Donations		5.2	27.9	35.1	15.3	
COVAX		114.3	87.6	37.1	9.2	•
Other		11.3	16.8	23.1	2.1	•
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	62.43
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	2.58
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.51
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.01
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 146
Date of Publication						•

				,		•
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	New Zealand
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	722.55
Bilateral Deals		2.3	52.9	130.3	475.7	720.48
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	2.07
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	79.4
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.1
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.76
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.23
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 147
Date of Publication						•

Micaragua		110	tes. The lest i ositivi	ty Nate and denomic 3	di velliance targets are n	idicative. Last updated off 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Nicaragua
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	164.18
Bilateral Deals		2.3	52.9	130.3	475.7	69.96
Direct Donations		5.2	27.9	35.1	15.3	7.46
COVAX		114.3	87.6	37.1	9.2	86.76
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	65.63
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.48
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	51.24
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	3.94
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 148
Date of Publication						Nov, 2020

Niger		NO	tes. The lest i ositivit	.y Nate and Genomic 3	ui veillance targets are	indicative. Last updated on 7 Apr 2
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Niger
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	130.9
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	1.69
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	9.21
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	6.15
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	87.34
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.34
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	14.16
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.01
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.12
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.06
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						29.2
Date approved						Jun 25, 2021
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate <sup>149</sup>
Date of Publication						Oct, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Nigeria
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	119.54
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	.71
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	18.83
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	4.52
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	50.17
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.09
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	29.56
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.06
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.22
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.24
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						400
Date approved						Sep 30, 2021
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						32.1
RDT diagnostic tests (USD mn.)						51.2
PPE (USD mn.)						26.7
Therapeutics – Oxygen (USD mn.)						29
Therapeutics – Others (USD mn.)						15.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 150
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	North Macedonia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	208.24
Bilateral Deals		2.3	52.9	130.3	475.7	81.63
Direct Donations		5.2	27.9	35.1	15.3	32.87
COVAX		114.3	87.6	37.1	9.2	26.52
Other		11.3	16.8	23.1	2.1	67.22
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	40.11
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	82.27
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.36
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	9.7
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.27
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 151
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Norway
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	265.15
Bilateral Deals		2.3	52.9	130.3	475.7	265.15
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	73.71
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	77.82
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	5.24
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	17.6
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	3.99
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 152
Date of Publication						•

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Oman
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	147.67
Bilateral Deals		2.3	52.9	130.3	475.7	133.57
Direct Donations		5.2	27.9	35.1	15.3	3.83
COVAX		114.3	87.6	37.1	9.2	10.28
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	57.9
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.08
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.13
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.22
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 15
Date of Publication						

- anistan				,		· · ·
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Pakistan
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	116.22
Bilateral Deals		2.3	52.9	130.3	475.7	22.04
Direct Donations		5.2	27.9	35.1	15.3	4.85
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	9.33
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	51.41
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.39
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	31.38
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.12
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.78
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.17
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						500
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 154
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Palau
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	259.38
Bilateral Deals		2.3	52.9	130.3	475.7	225.26
Direct Donations		5.2	27.9	35.1	15.3	34.11
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	94.71
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	100
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	•
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.42
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 155
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Panama
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	289.1
Bilateral Deals		2.3	52.9	130.3	475.7	253.1
Direct Donations		5.2	27.9	35.1	15.3	11.48
COVAX		114.3	87.6	37.1	9.2	24.51
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	69.31
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.23
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.62
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	4.25
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.37
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.2
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						

Papua New Guinea	Notes: The Test Positivity Rate and Genomic Surveillance targets are indicative. Last updated on 7 Apr 2						
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Papua New Guinea	
Vaccines							
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	102.4	
Bilateral Deals		2.3	52.9	130.3	475.7	0	
Direct Donations		5.2	27.9	35.1	15.3	2.4	
COVAX		114.3	87.6	37.1	9.2	100	
Other		11.3	16.8	23.1	2.1	0	
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	2.82	
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	44.62	
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01	
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	10.44	
Progress Towards 70% Full Vaccine Coverage						Off track	
Diagnostics							
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.06	
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•	
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	9.91	
Financing for Vaccines, Diagnostics, Treatments, PPE							
AVAT orders placed						•	
World Bank financing for vaccines (USD mn.)						30	
Date approved						Jun 22, 2021	
Date effective						•	
ADB financing for vaccines (USD mn.)						•	
Global Fund COVID-19 Response Mechanism							
PCR diagnostic tests (USD mn.)						3.4	
RDT diagnostic tests (USD mn.)						1	
PPE (USD mn.)						0	
Therapeutics – Oxygen (USD mn.)						1.2	
Therapeutics – Others (USD mn.)						0	
IMF-WB Joint Debt Sustainability Analysis							
Risk of External Debt Distress						High	
Risk of Overall Debt Distress						High <sup>157</sup>	
Date of Publication						Jun, 2020	

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Paraguay
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	174.1
Bilateral Deals		2.3	52.9	130.3	475.7	100.42
Direct Donations		5.2	27.9	35.1	15.3	39.92
COVAX		114.3	87.6	37.1	9.2	33.76
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	46.15
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.1
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.25
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	6.54
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.2
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.7
RDT diagnostic tests (USD mn.)						.2
PPE (USD mn.)						.1
Therapeutics – Oxygen (USD mn.)						1.3
Therapeutics – Others (USD mn.)						.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 1
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	<b>LMIC</b>	UMIC	HIC	Peru
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	471.65
Bilateral Deals		2.3	52.9	130.3	475.7	437.79
Direct Donations		5.2	27.9	35.1	15.3	9.1
COVAX		114.3	87.6	37.1	9.2	24.77
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	78.37
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.44
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.4
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.54
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.1
RDT diagnostic tests (USD mn.)						1.2
PPE (USD mn.)						2.2
Therapeutics – Oxygen (USD mn.)						.8
Therapeutics – Others (USD mn.)						.8
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 159
Date of Publication						

Date of Publication

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Poland
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	59.2
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	51.22
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.88
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	15.06
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.34
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 161
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Dortugal
	Targets	LIC	LIVIIC	OWIC	THE	Portugal
Vaccines (Dans of Dans lating)	. 440	422.4	405.2	225.6	502.2	C20.04
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	92.6
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	70.01
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.11
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Goal met
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	4.3
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	20.39
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.86
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 162
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Qatar
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	250.06
Bilateral Deals		2.3	52.9	130.3	475.7	227.21
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	22.85
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	88.5
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.24
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.28
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.34
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 163
Date of Publication						•

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Romania
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	42.28
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	62.26
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.96
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	5.65
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.46
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.9
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 10
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>Russian Federation</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	200
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	200
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	50
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.71
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	9.41
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.09
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 165
Date of Publication						

<u>kwanda</u>		110	tes. The lest rositivi	divellance targets are	mulcative. Last updated on 7 Apr.	
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Rwanda
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	196.31
Bilateral Deals		2.3	52.9	130.3	475.7	8.48
Direct Donations		5.2	27.9	35.1	15.3	29.42
COVAX		114.3	87.6	37.1	9.2	112.54
Other		11.3	16.8	23.1	2.1	45.87
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	61.36
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	77.28
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.16
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	62.92
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.54
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.04
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.61
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						45
Date approved						Apr 16, 2021
Date effective						Jun 21, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.7
RDT diagnostic tests (USD mn.)						3.1
PPE (USD mn.)						3.4
Therapeutics – Oxygen (USD mn.)						2.1
Therapeutics – Others (USD mn.)						.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 166
Date of Publication						Jul, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	San Marino
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	220.7
Bilateral Deals		2.3	52.9	130.3	475.7	220.7
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	69.4
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	12.03
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Saudi Arabia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	196.72
Bilateral Deals		2.3	52.9	130.3	475.7	191.71
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	5.02
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	69.58
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.18
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.36
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.73
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.16
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Senegal
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	127.6
Bilateral Deals		2.3	52.9	130.3	475.7	1.16
Direct Donations		5.2	27.9	35.1	15.3	1.89
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	44.54
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	6.04
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	41.75
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	17.3
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.06
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.59
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	4.3
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						134
Date approved						Jun 2, 2021
Date effective						Jul 9, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						2.2
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						2.9
Therapeutics – Oxygen (USD mn.)						1.1
Therapeutics – Others (USD mn.)						.9
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 171
Date of Publication						Jun, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Serbia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	136.6
Bilateral Deals		2.3	52.9	130.3	475.7	121.84
Direct Donations		5.2	27.9	35.1	15.3	5.59
COVAX		114.3	87.6	37.1	9.2	9.17
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	47.58
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.51
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.77
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	12.47
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.04
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.2
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 172
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Seychelles
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	309.37
Bilateral Deals		2.3	52.9	130.3	475.7	25.84
Direct Donations		5.2	27.9	35.1	15.3	127.39
COVAX		114.3	87.6	37.1	9.2	156.14
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	81.04
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	65.31
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.04
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Goal met
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	2.71
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	2.72
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						•
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Sierra Leone
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	112.04
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	5.04
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	7
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	13.82
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	100
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.64
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	16.86
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.08
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.14
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.8
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						8.5
Date approved						May 28, 2021
Date effective						Jun 28, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						6.7
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						4.9
Therapeutics – Oxygen (USD mn.)						1.3
Therapeutics – Others (USD mn.)						.5
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>174</sup>
Date of Publication						Jul, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Singapore
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	279.65
Bilateral Deals		2.3	52.9	130.3	475.7	263.74
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	15.91
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	91.12
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.15
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	12.3
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	10.01
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.33
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 17
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Slovak Republic
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	665.84
Bilateral Deals		2.3	52.9	130.3	475.7	665.56
Direct Donations		5.2	27.9	35.1	15.3	.27
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	50.72
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	64.22
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	3.88
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	27.5
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.75
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						
Date of Publication						•

<u></u>				•		<u> </u>
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Slovenia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	58.7
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	53.82
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	5.69
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	19.2
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	6.51
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 177
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Solomon Islands
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	142.73
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	42.73
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	17.39
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	54.08
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.14
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	29.2
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.52
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.2
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						.8
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 178
Date of Publication						Jun, 2020

Somalia		110		.y Nate and denomic 5	di velliance targets are	indicative. Last updated on 7 Ap
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Somalia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	125.5
Bilateral Deals		2.3	52.9	130.3	475.7	1.22
Direct Donations		5.2	27.9	35.1	15.3	4.28
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	8.26
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	42.73
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.04
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	29.28
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.03
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.13
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						45
Date approved						Sep 28, 2021
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						2.6
RDT diagnostic tests (USD mn.)						.9
PPE (USD mn.)						.9
Therapeutics – Oxygen (USD mn.)						2.9
Therapeutics – Others (USD mn.)						.4
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						In distress
Risk of Overall Debt Distress						In distress 179
Date of Publication						Nov, 2020

COVID-19 Health Tools	<b>Targets</b>	LIC	<b>LMIC</b>	UMIC	HIC	South Africa
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	117.03
Bilateral Deals		2.3	52.9	130.3	475.7	101.6
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	15.44
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	29.98
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	100
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.1
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.38
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	5.87
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.97
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	South Sudan
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	121.4
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	1.4
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	4.24
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	61.81
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	8.64
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.07
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	1.87
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.98
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						63.93
Date approved						Jun 28, 2021
Date effective						Jul 1, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.5
RDT diagnostic tests (USD mn.)						.5
PPE (USD mn.)						2.5
Therapeutics – Oxygen (USD mn.)						.4
Therapeutics – Others (USD mn.)						1.3
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>181</sup>
Date of Publication						Mar, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Spain
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	86.09
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	59.68
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.07
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	3.08
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	17.4
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.02
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 18
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Sri Lanka
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	259.03
Bilateral Deals		2.3	52.9	130.3	475.7	72.1
Direct Donations		5.2	27.9	35.1	15.3	18.55
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	88.38
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	67.11
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.09
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	17.62
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.24
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	3.96
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.51
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)					100	80.51
Date approved					Sep 28, 2021	Apr 27, 2021
Date effective					Sep 28, 2021	May 17, 2021
ADB financing for vaccines (USD mn.)						150
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.1
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						.6
Therapeutics – Oxygen (USD mn.)						.7
Therapeutics – Others (USD mn.)						.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 183
Date of Publication						•

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	St Kitts and Nevis
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	128.87
Bilateral Deals		2.3	52.9	130.3	475.7	7.48
Direct Donations		5.2	27.9	35.1	15.3	76.57
COVAX		114.3	87.6	37.1	9.2	40.34
Other		11.3	16.8	23.1	2.1	4.48
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	49.11
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	87.63
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.2
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1912.39
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.32
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.33
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 184
Date of Publication						•

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	St Lucia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	164.94
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	52.41
COVAX		114.3	87.6	37.1	9.2	112.53
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	28.63
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	39.41
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	58.22
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.58
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	4.97
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.62
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 185
Date of Publication						

						·
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Suriname
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	179.49
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	155.15
COVAX		114.3	87.6	37.1	9.2	24.33
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	40.12
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	61.9
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.04
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	14.1
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.34
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 188
Date of Publication						

				,		<u> </u>
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Sweden
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	628.94
Bilateral Deals		2.3	52.9	130.3	475.7	628.94
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	74.98
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	72.72
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.17
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	4.74
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	16.24
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	7.05
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 189
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Switzerland
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	837.02
Bilateral Deals		2.3	52.9	130.3	475.7	837.02
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	68.57
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	74.96
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.55
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	39.3
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	3.86
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 19
Date of Publication						

- y ab cpab				•		· · · · · · · · · · · · · · · · · · ·
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Syrian Arab Republic
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	129.85
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	9.85
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	7.44
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	25.69
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	55.68
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.01
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	33.3
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.16
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 191
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Tanzania
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	82.44
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	2.44
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	4.99
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	62.73
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	0
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	7.2
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.01
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.01
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						No
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						21.1
RDT diagnostic tests (USD mn.)						17.1
PPE (USD mn.)						18.4
Therapeutics – Oxygen (USD mn.)						19.3
Therapeutics – Others (USD mn.)						3.5
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate 193
Date of Publication						Sep, 2021

				,		·
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Thailand
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	333.1
Bilateral Deals		2.3	52.9	130.3	475.7	321.65
Direct Donations		5.2	27.9	35.1	15.3	11.45
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	71.93
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.25
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.74
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	36.51
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.47
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						2.6
RDT diagnostic tests (USD mn.)						.7
PPE (USD mn.)						9
Therapeutics – Oxygen (USD mn.)						.8
Therapeutics – Others (USD mn.)						2.1
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 194
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Timor-Leste
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	123.22
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	23.22
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	43.95
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.42
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	25.34
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.23
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	2.18
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.56
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						2.1
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						.7
Therapeutics – Oxygen (USD mn.)						.3
Therapeutics – Others (USD mn.)						.4
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Low
Risk of Overall Debt Distress						Low 195
Date of Publication						Mar, 2019

logo		110	tes. The lest i ositivi		- di velliance targets are	indicative. Last updated on 7 Apr
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Togo
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	154.92
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	7.74
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	47.18
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	18.37
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	46.37
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	31.92
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.05
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.75
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.97
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						29.5
Date approved						Jun 10, 2021
Date effective						Jun 30, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						4.1
RDT diagnostic tests (USD mn.)						1.1
PPE (USD mn.)						1.5
Therapeutics – Oxygen (USD mn.)						.2
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						High <sup>196</sup>
Date of Publication						Apr, 2020

longa		110	tes. The lest i ositivi	Ty Nate and Genomic 5	di veillance targets are il	luicative. Last apaated on 7 Apr 2
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Tonga
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	172.2
Bilateral Deals		2.3	52.9	130.3	475.7	8.56
Direct Donations		5.2	27.9	35.1	15.3	80.46
COVAX		114.3	87.6	37.1	9.2	83.18
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	65.83
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.53
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	45.06
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						5.5
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>197</sup>
Date of Publication						Jan, 2025

						·
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>Trinidad and Tobago</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	297.61
Bilateral Deals		2.3	52.9	130.3	475.7	106.89
Direct Donations		5.2	27.9	35.1	15.3	93.88
COVAX		114.3	87.6	37.1	9.2	39.85
Other		11.3	16.8	23.1	2.1	57.01
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	50.56
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	64.76
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.02
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.86
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	20.2
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	1.71
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 198
Date of Publication						

Tunisia		No	tes: The Test Positivi	ty Rate and Genomic S	urveillance targets are	indicative. Last updated on 7 Apr 20
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Tunisia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	174.65
Bilateral Deals		2.3	52.9	130.3	475.7	4.19
Direct Donations		5.2	27.9	35.1	15.3	43.69
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	46.77
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	53.2
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	78.08
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	26.08
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.22
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	18.74
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.11
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						100
Date approved						Mar 26, 2021
Date effective						May 26, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						.1
RDT diagnostic tests (USD mn.)						.8
PPE (USD mn.)						.1
Therapeutics – Oxygen (USD mn.)						1.1
Therapeutics – Others (USD mn.)						.8
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 199
Date of Publication						

- in the y				•		· · · · · · · · · · · · · · · · · · ·
COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Turkey
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	282.21
Bilateral Deals		2.3	52.9	130.3	475.7	282.21
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	62.31
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.3
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	5.14
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.6
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 200
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Uganda
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	126.84
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	3.37
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	23.47
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	17.01
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	48.09
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	52.02
Progress Towards 70% Full Vaccine Coverage						On track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.05
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.4
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.6
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate <sup>202</sup>
Date of Publication						Jun, 2021

				•	
	ш		ra		
L	л	ĸ	ıa	ш	 t

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Ukraine
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	305.51
Bilateral Deals		2.3	52.9	130.3	475.7	170.71
Direct Donations		5.2	27.9	35.1	15.3	8.79
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	46.01
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	34.86
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	67.95
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.09
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	27.38
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	1.31
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.02
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						90
Date approved						May 10, 2021
Date effective						Aug 1, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 203
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>United Arab Emirates</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	270.17
Bilateral Deals		2.3	52.9	130.3	475.7	268.18
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	1.99
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	96.32
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	90.91
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.1
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	24.74
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	.1
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.29
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 204
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>United Kingdom</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	669.34
Bilateral Deals		2.3	52.9	130.3	475.7	668.55
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	.79
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	72.57
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	75.25
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.05
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	8.39
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	11.2
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	11.87
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 20
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	<b>United States</b>
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	465.58
Bilateral Deals		2.3	52.9	130.3	475.7	465.58
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	0
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	65.47
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	81.8
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.07
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	2.1
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	2.5
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	3.82
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 2
Date of Publication						•

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Uruguay
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	232.01
Bilateral Deals		2.3	52.9	130.3	475.7	213.39
Direct Donations		5.2	27.9	35.1	15.3	14.35
COVAX		114.3	87.6	37.1	9.2	4.27
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	81.83
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	100
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.24
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	2.01
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	9.77
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.09
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 20
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Uzbekistan
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	187.56
Bilateral Deals		2.3	52.9	130.3	475.7	106.08
Direct Donations		5.2	27.9	35.1	15.3	1.48
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	41.37
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	83.94
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.19
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	24.38
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.45
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.04
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Low
Risk of Overall Debt Distress						Low 208
Date of Publication						Apr, 2021

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Vanuatu
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	153.14
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	73.14
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	27.09
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	58.71
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	0
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	42.16
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	•
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.04
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						3.88
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						Moderate
Risk of Overall Debt Distress						Moderate <sup>209</sup>
Date of Publication						Aug, 2021

10.10140.147				•		•
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Venezuela, RB
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	161.39
Bilateral Deals		2.3	52.9	130.3	475.7	94.91
Direct Donations		5.2	27.9	35.1	15.3	1.74
COVAX		114.3	87.6	37.1	9.2	64.74
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	49.77
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	81.73
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	0
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	•
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	.01
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.09
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.9
RDT diagnostic tests (USD mn.)						.1
PPE (USD mn.)						5.6
Therapeutics – Oxygen (USD mn.)						.3
Therapeutics – Others (USD mn.)						2
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 21
Date of Publication						

COVID-19 Health Tools	<b>Targets</b>	LIC	LMIC	UMIC	HIC	Vietnam
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	296.07
Bilateral Deals		2.3	52.9	130.3	475.7	189.37
Direct Donations		5.2	27.9	35.1	15.3	26.7
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	79.2
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	89.54
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.26
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	33.06
Progress Towards 70% Full Vaccine Coverage						<b>Goal met</b>
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.02
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	96.33
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.04
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						0
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						0
Therapeutics – Oxygen (USD mn.)						0
Therapeutics – Others (USD mn.)						0
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	West Bank and Gaza
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	255.47
Bilateral Deals		2.3	52.9	130.3	475.7	115.36
Direct Donations		5.2	27.9	35.1	15.3	40.11
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	33.74
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	66.32
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.03
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	20.08
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	> 1	.06	.65	1.30	50.02	2.86
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	19.62
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.02
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						•
RDT diagnostic tests (USD mn.)						•
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						•
Risk of Overall Debt Distress						. 212
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Yemen, Rep
Vaccines						· ·
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	120
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	0
COVAX		114.3	87.6	37.1	9.2	120
Other		11.3	16.8	23.1	2.1	0
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	1.33
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	32.12
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.01
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	6.3
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	0
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	•
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	•
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						•
World Bank financing for vaccines (USD mn.)						20.0116
Date approved						Jun 17, 2021
Date effective						Jul 16, 2021
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						
RDT diagnostic tests (USD mn.)						
PPE (USD mn.)						•
Therapeutics – Oxygen (USD mn.)						•
Therapeutics – Others (USD mn.)						•
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						
Risk of Overall Debt Distress						. 213
Date of Publication						

COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Zambia
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	109.33
Bilateral Deals		2.3	52.9	130.3	475.7	0
Direct Donations		5.2	27.9	35.1	15.3	6.08
COVAX		114.3	87.6	37.1	9.2	80
Other		11.3	16.8	23.1	2.1	23.26
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	11.82
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	54.94
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.06
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	23.06
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.12
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	3.33
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.43
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						24
Date approved						Jun 28, 2021
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						12.8
RDT diagnostic tests (USD mn.)						3.7
PPE (USD mn.)						11.8
Therapeutics – Oxygen (USD mn.)						10.4
Therapeutics – Others (USD mn.)						4.6
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						High
Risk of Overall Debt Distress						High <sup>214</sup>
Date of Publication						Jul, 2019

COVID 40 Health Tools	Tavanta	116	LDAIC	LIDAIC	IIIC	
COVID-19 Health Tools	Targets	LIC	LMIC	UMIC	HIC	Zimbabwe
Vaccines						
Secured Vaccines (Doses, % of Population)	> 140	133.1	185.2	225.6	502.3	266.01
Bilateral Deals		2.3	52.9	130.3	475.7	53.01
Direct Donations		5.2	27.9	35.1	15.3	79.88
COVAX		114.3	87.6	37.1	9.2	100
Other		11.3	16.8	23.1	2.1	33.13
% of Population Fully Vaccinated as of Today		13.06	38.8	48.1	73.1	23.71
Percent of Delivered Vaccine Doses that were Administered		62.7	69.1	76.4	77.7	44.02
Current Rate of Daily Vaccination (per 100 people)		.22	.20	.23	.10	.75
COVAX AMC Allocation (Course, per 100 people)		22.8	27.4	7.3	0	16.98
Progress Towards 70% Full Vaccine Coverage						Off track
Diagnostics						
Daily Testing Rate (per 1000 people)	>1	.06	.65	1.30	50.02	.2
Test Positivity Rate (%, 7-day average)	< 5	3.59	8.47	7.90	22.4	4.23
Genomic Surveillance (Sequences Shared, % of Cases)	> 1-5	1.23	1.01	0.48	2.65	.38
Financing for Vaccines, Diagnostics, Treatments, PPE						
AVAT orders placed						Yes
World Bank financing for vaccines (USD mn.)						•
Date approved						•
Date effective						•
ADB financing for vaccines (USD mn.)						•
Global Fund COVID-19 Response Mechanism						
PCR diagnostic tests (USD mn.)						1.1
RDT diagnostic tests (USD mn.)						0
PPE (USD mn.)						30.2
Therapeutics – Oxygen (USD mn.)						5.4
Therapeutics – Others (USD mn.)						.4
IMF-WB Joint Debt Sustainability Analysis						
Risk of External Debt Distress						In distress
Risk of Overall Debt Distress						In distress 215
Date of Publication						Feb, 2020